title: Three clinical cases of nonrespiratory acidosis in kidney transplant recipients receiving anti-CMV therapy.
abstract: BACKGROUND
  To preserve kidney graft function it is necessary to use ganciclovir or valganciclovir as a therapy for fresh CMV infection or prophylaxis in high-risk kidney transplant recipients. Ganciclovir-induced lactic acidosis has thus far not been reported.
  
  
  METHODS
  Three cases of nonrespiratory acidosis in kidney transplant recipients receiving ganciclovir or valganciclovir as anti-CMV therapy or prophylaxis are presented. Lactic acidosis developed in 2 patients, and the other patient had nonrespiratory acidosis of unknown origin. The possible mechanism of the development of lactic acidosis in presented cases is explored.
  
  
  CONCLUSIONS
  The analysis of the described cases cannot eliminate the potential negative influence of anti-CMV therapy on acid-base equilibrium, especially with coexisting active viral infection.
authors: Department of Nephrology and Transplantology, Pomeranian Medical University, Szczecin, Poland. askodom@poczta.onet.pl
authors: Joanna
authors: J
authors: Kabat-Koperska
authors: Karolina
authors: K
authors: Kędzierska
authors: Edyta
authors: E
authors: Gołembiewska
authors: Małgorzata
authors: M
authors: Marchelek-Myśliwiec
authors: Grażyna
authors: G
authors: Dutkiewicz
authors: Kazimierz
authors: K
authors: Ciechanowski
mesh_terms: D000138:Acidosis / Q000209:etiology*; D000998:Antiviral Agents / Q000009:adverse effects*; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged
chemical_list: D000998:Antiviral Agents; D015774:Ganciclovir